Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aptiv Solutions Growing: Opens New Office in North Carolina

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
New office is located at 4505 Emperor Boulevard in the Imperial Center.

Aptiv Solutions has announced the opening of a new office in Durham, North Carolina.

The new office is located at 4505 Emperor Boulevard in the Imperial Center, an elite business park convenient to Raleigh, Durham, Chapel Hill, Cary and Research Triangle Park.

Aptiv Solutions and its subsidiary Trio Clinical Resourcing previously resided in separate offices in Raleigh and Morrisville.

The decision to combine the offices arose from growth of staff and the desire to co-locate the North Carolina based teams.

The new office includes team members from the clinical, data management and biostatistics, regulatory, translational sciences, medical consulting, pharmacovigilance, quality assurance, proposal development, information technology, finance, business development and human resources teams for Aptiv Solutions and the Trio Clinical Resourcing team.

“We are delighted to have our Aptiv Solutions and Trio Clinical Resourcing teams all under one roof in the new Durham, North Carolina office,” commented Pat Donnelly, Chairman and CEO of Aptiv Solutions.

Donnelly continued, “We continue to experience rapid growth as we expand to meet the expansion in our client base. Our new office not only accommodates our current staff levels, but allows for the anticipated future growth of our North Carolina operations”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,400+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aptiv Solutions to be Acquired by ICON
Combined companies provide unrivalled capabilities for adaptive and medical device trials worldwide.
Monday, March 31, 2014
Tufts CSDD Study Finds Adoption of Adaptive Clinical Trial Designs is Increasing
Report shows growing acceptance by pharmaceutical companies and regulatory agencies.
Friday, May 24, 2013
Scientific News
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!